hotspot -WSS

hotspot

author：hotspot 2025-10-01 22:59:47 - browse：68

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Listen: A conversation with researcher Kevin Esvelt on biosecurity

entertainment

WSS

H5N1 virus can be tracked in retail milk, scientists say

Eyeing GLP

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Diversity in clinical trials starts with building trust, experts say

H5N1 virus can be tracked in retail milk, scientists say

Diversity in clinical trials starts with building trust, experts say

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

H5N1 bird flu outbreak: Second human case reported, in Michigan

Peter Hotez and the public health issue of online harassment

More tobacco lobbyists active in statehouses

Trump demands the U.S. pay no more for drugs than other countries … again

Why does health care cost so much? A reading guide

Alkermes shareholders re

MassMutual is introducing free genetic testing for members

The high cost of giving birth even with insurance

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

explore

Listen: More tumult at BIO & coercive care for sickle cell patients

H5N1 bird flu virus started spreading in cows in Texas in December

Bird flu in milk supply is likely coming from asymptomatic cows

Dogs on Prozac: What pet anti

H5N1 bird flu virus started spreading in cows in Texas in December

FTC falls short on scrutinizing hospital mergers, study says

hotspot

focus

entertainment

explore